Syncom Formulations (India) Ltd
Ticker: SYNCOMF
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
16.31
Market Cap
1539.81
Debt/Equity
0.0134
ROE %
15.688
PB
4.5003
Promoter %
50.569
Pledge %
0.000
1Y Rev Growth %
74.220
5Y Rev Growth %
NP Margin %
10.248
NP Margin 5Y Avg %
Trading Reference
1M Return %
-8.375
6M Return %
-6.264
1Y Return %
-22.444
% Away 52W High
46.352
% Away 52W Low
15.674
Daily Volume
943615
Investment Verdict
Hold
Score 69/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 22/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Syncom Formulations (India) Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend. If it breaks above the resistance level, there is a strong probability of a price increase. However, if it falls below the support, a decline is likely.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
B
BGR Energy Systems Ltd
BGR Energy Systems Ltd shows potential in a growing sector, but faces challenges in execution and profitability consistency.
View details
L
Laxmi Dental Ltd
Laxmi Dental Ltd shows potential in a growing sector, but faces significant challenges in profitability and valuation metrics. Caution is advised.
View details
T
TTK Healthcare Ltd
TTK Healthcare Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
M
MIC Electronics Ltd
MIC Electronics Ltd faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
T
Tarsons Products Ltd
Tarsons Products Ltd shows potential with a decent score, but investors should be cautious due to some risks in profitability and execution.
View details
J
JNK India Ltd
JNK India Ltd shows potential but faces significant challenges in growth and valuation, making it a risky investment at this time.
View details
A
Antony Waste Handling Cell Ltd
Antony Waste Handling Cell Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
S
Sanghi Industries Ltd
Sanghi Industries Ltd shows potential for growth in a vital sector, but faces challenges in consistency and liquidity.
View details
R
Rishabh Instruments Ltd
Rishabh Instruments Ltd shows potential but faces challenges in growth consistency and valuation. Investors should be cautious.
View details
S
Sigachi Industries Ltd
Sigachi Industries Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
C
Confidence Petroleum India Ltd
Confidence Petroleum India Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics, making it a risky investment at this time.
View details
S
Stallion India Fluorochemicals Ltd
Stallion India Fluorochemicals Ltd presents a mixed outlook with potential in the fluorochemical sector, but faces challenges in profitability and valuation metrics.
View details
C
Concord Control Systems Ltd
Concord Control Systems Ltd shows potential in a growing sector, but faces challenges in consistent growth and valuation metrics.
View details
O
Orient Green Power Company Ltd
The company faces significant challenges in growth, profitability, and market sentiment, making it a risky investment.
View details
S
Satin Creditcare Network Ltd
Satin Creditcare Network Ltd shows decent potential but carries risks related to profitability and market conditions.
View details
O
Omaxe Ltd
Omaxe Ltd presents several risks with inconsistent growth and profitability metrics, alongside high valuation concerns.
View details
Business Overview
Syncom Formulations (India) Ltd is a prominent player in the pharmaceutical sector, specializing in the development and manufacturing of quality formulations. Catering to healthcare providers and patients, the company focuses on delivering affordable and effective medications. With a commitment to innovation and compliance with international standards, Syncom plays a crucial role in enhancing healthcare accessibility in India. Its robust product portfolio and strategic partnerships position it well for growth in a competitive market.
- Established leader in pharmaceutical formulations
- Focus on affordable healthcare solutions
- Strong commitment to quality and compliance
- Diverse product portfolio catering to various therapeutic areas
- Strategic partnerships enhancing market reach
Investment Thesis
Syncom Formulations (India) Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and profitability in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services expansion aligns with industry trends, offering substantial growth potential.
- Valuation metrics indicate Syncom is undervalued compared to its peers, presenting a buying opportunity.
- Robust financials and consistent performance signal reliability and resilience.
- Strategic initiatives in R&D and market expansion support long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for generic drugs
- Expansion into international markets
- Strong product pipeline
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in drug approvals
- High competition in pharmaceuticals
- Dependency on key suppliers
- Fluctuating raw material costs
Peer Perspective
Syncom Formulations trades at a discount to peers like Aarti Drugs and Granules India, primarily due to margin volatility. A sustained improvement in margins could trigger a rerating, aligning it closer to its competitors.
Future Outlook
Syncom Formulations (India) Ltd is poised for growth, driven by expanding market opportunities. However, successful execution and stringent cost control will be crucial to fully realize its potential in the competitive pharmaceutical landscape.
AI FAQs for Retail Users
- Q: What does Syncom Formulations (India) Ltd do?A: Syncom Formulations specializes in manufacturing and marketing pharmaceutical formulations and products.
- Q: Is Syncom Formulations listed on Indian stock exchanges?A: Yes, Syncom Formulations is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
- Q: What factors influence Syncom Formulations' stock price?A: Stock price can be influenced by company performance, market trends, and overall economic conditions.
- Q: How can I invest in Syncom Formulations?A: You can invest through a brokerage account that allows trading on Indian stock exchanges.
- Q: Are there any risks associated with investing in Syncom Formulations?A: As with any investment, risks include market volatility and company-specific challenges.
📊 Stock Investment Checklist (100 Points)
Syncom Formulations (India) Ltd • Updated: 2025-09-17 17:16:14
-
8BusinessHighPharmaceutical sector shows growth potential, but competition is high.
-
10GrowthHighInconsistent revenue growth over the past few years.
-
10ProfitabilityHighModerate ROE and ROCE, but cash flow is not stable.
-
9ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
7BalanceHighManageable debt levels but low liquidity ratios.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth drivers identified; execution risks are significant.
-
1TechnicalsLowWeak market sentiment and poor price action.
Final Score & Verdict
Score 48 / 100
• Risky
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 60/100
- Growth Potential: 65/100
- Profitability: 55/100
- Governance: 50/100
- Market Confidence: 60/100